We read with great interest the article by Derksen JWG et al. [
[1]
] The authors conducted a meta-analysis, which demonstrated that compared to 5-fluorouracil
(5-FU)/capecitabine-based therapy, the S-1-based therapy showed non-inferiority for
progression-free survival in patients with metastatic colorectal cancer. The study
provided further evidence support for the clinical application of S-1. However, we
have some concerns about the co-interventions in this study.- Derksen J.W.G.
- Smit K.C.
- May A.M.
- Punt C.J.A.
Systematic review and non-inferiority meta-analysis of randomised phase II/III trials
on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment
of patients with metastatic colorectal cancer.
Eur J Cancer. 2022 May; 166: 73-86
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancer.Eur J Cancer. 2022 May; 166: 73-86
- Higgins J.P.T. Thomas J. Chandler J. Cumpston M. Li T. Page M.J. Welch V.A. Cochrane Handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane. 2022 (Available from:)
- Getting the "balance" right in clinical trials.BMJ. 2021 Nov 24; 375: n2869
- Clinician-trialist rounds: 5. Cointervention bias--how to diagnose it in their trial and prevent it in yours.Clin Trials. 2011 Aug; 8: 440-442
- Chapter 3: defining the criteria for including studies and how they will be grouped for the synthesis.(updated February 2022). Cochranein: Higgins J.P.T. Thomas J. Chandler J. Cumpston M. Li T. Page M.J. Welch V.A. Cochrane Handbook for systematic reviews of interventions version 6.3. 2022 (Available from:)
- S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.Ann Oncol. 2018 Mar 1; 29: 624-631
Article info
Publication history
Published online: October 28, 2022
Accepted:
September 12,
2022
Received:
July 29,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Systematic review and non-inferiority meta-analysis of randomised phase II/III trials on S-1-based therapy versus 5-fluorouracil- or capecitabine-based therapy in the treatment of patients with metastatic colorectal cancerEuropean Journal of CancerVol. 166
- PreviewS-1 is an oral fluoropyrimidine that is increasingly used in Western countries for the treatment of metastatic colorectal cancer (mCRC). We conducted a non-inferiority meta-analysis on the efficacy of S-1-based therapy versus 5-fluorouracil (5-FU)- or capecitabine-based therapy in the treatment of patients with mCRC.
- Full-Text
- Preview
